The Israel Amyloidosis Association held its annual conference on 23 October 2026, bringing together approximately 200 patients, clinicians and researchers from across Israel. The event took place just ahead of International Amyloidosis Day on 26 October and featured presentations from leading Israeli experts in haematology, cardiology and neurology.

Alongside a series of lectures and panel discussions, the association showcased its ongoing work to improve treatment access, advance research and strengthen support for people living with amyloidosis.

Expanding access to CAR T-Cell therapy

One of the conference’s key highlights was the association’s role in supporting the development of CAR T-Cell therapy for AL amyloidosis in Israel.

While CAR-T programmes in Israel were originally developed for multiple myeloma, patients with AL amyloidosis were initially excluded due to the small size of the patient population. Through advocacy, stakeholder engagement, ongoing discussions and financial support, the Israel Amyloidosis Association helped advance efforts to make the treatment available to amyloidosis patients.

As a result, Israel has become the first country in the world to offer CAR-T therapy to patients with amyloidosis, representing a significant milestone for the community.

Mosaic project nears completion

The conference also highlighted progress on the Mosaic Project, a national initiative that collects DNA samples to support AI-driven, big-data health research.

The association is working to establish a dedicated subgroup within the project comprising DNA samples from people living with AL amyloidosis across Israel. The initiative is now approaching completion and is expected to create new opportunities for research, helping to improve understanding of the disease and support future treatment advances.

AI tool supports patients accessing social rights

Another major focus of the event was CLADIS, an AI-powered tool developed to help patients navigate Israel’s complex social benefits system.

Many patients currently rely on paid support services to access benefits and entitlements. In response, the Israel Amyloidosis Association initiated the development of CLADIS to provide free guidance and support to its members.

Recognising both the need for the project and its innovative approach, Myeloma Patients Europe (MPE) awarded the association a €5,000 grant to support its development.

CLADIS has now completed development for amyloidosis and several other diseases and is currently undergoing beta testing with patients. The platform helps users access a range of benefits, including disability allowances, special services, long-term care support, income tax exemptions and disabled parking permits.

The Israel Amyloidosis Association expressed its appreciation to MPE for supporting the initiative and helping bring the project closer to patients who need it and MPE is happy to help support such vital work!